David Arthur, Salarius CEO

FDA lifts par­tial hold on Salarius' Ew­ing sar­co­ma drug tri­al

Hous­ton biotech Salarius Phar­ma­ceu­ti­cals has re­ceived some pos­i­tive news from the FDA.

Salarius an­nounced Tues­day that the agency re­moved a par­tial clin­i­cal hold from its Phase I/II tri­al for its LSD1 in­hibitor se­clidem­stat to treat the bone can­cer Ew­ing sar­co­ma. Last year, Salarius de­cid­ed to pause new en­roll­ments when an in­di­vid­ual died af­ter tak­ing the treat­ment, and Salarius re­port­ed the de­tails to the FDA. While the cause of death re­mains un­clear, it did qual­i­fy as a sus­pect­ed un­ex­pect­ed se­ri­ous ad­verse re­ac­tion (SUSAR).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.